welcome to the website of the

17th St.Gallen International Breast Cancer Conference 2021

17 – 21 March 2021, online worldwide

 

The scientific chairs and the organizers invite you to the fully virtual 17th St.Gallen International Breast Cancer Conference from 17 to 21 March 2021! Experts of all major cooperative groups and centres worldwide actively engaged in basic and clinical research as well as in clinical management of patients with breast cancer will present their latest data, critically reviewed by leading specialists in the field, culminating in the famous Consensus Panel.

 

Preparations for the first ever virtual St. Gallen International Breast Cancer Conference 2021 are well under way and we are pleased to share some exciting programme news with you:

  • all traditional scientific sessions will be available on demand, so you can flexibly access and watch them starting one week prior to the official start of the conference
  • new interactive live discussion sessions featuring the top experts in the respective fields will take place in time-zone-sensitive session slots
  • audience participation will be encouraged and delegates have the opportunity to submit questions and contributions to the faculty prior to the conference or live in our discussion sessions
  • in order to allow even more room for discussions on early breast cancer care, the 2021 Consensus will be split out over the weekend, taking place on Saturday and Sunday for the first time

> Find out more about the programme

> Register now and be part of this unique experience – let’s make SG-BCC 2021 unforgettable!

> COVID-19 Update

chairs

 

Meet our chairs:

Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn, c/o Tumor and Breast Center ZeTuP St.Gallen / Switzerland

 

Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland

 

Scientific Programme-Chairpersons
Harold Burstein, Boston/MA, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Meredith Regan, Boston/MA, USA
Hans-Jörg Senn, St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, Boston/MA, USA

conference programme

Accelerating access to innovation in early breast cancer

 

This year, all delegates will be able to access and watch all our high-quality scientific lectures a week prior to the official start of the conference.

During the official conference days, live discussion sessions will take place during afternoon hours (CET) in order to ensure comfortable access for delegates from all over the world. All speakers from the respective on-demand session will be present to further discuss their lectures.

Be part of the scientific dialogue: Submit your questions for all scientific lectures as well as the renowned consensus (this year taking place as an extended version on both Saturday and Sunday) and join the scientific discussion.
Questions and discussion contributions can be submitted during the online registration process, while watching the scientific lectures or during the live discussion sessions.

The consensus session will take place on both Saturday and Sunday, allowing more room for discussion. Make sure to mark the dates in your calendar and regularly check our website in order to stay up-to-date with our programme schedule.

Get ready for the most interactive St.Gallen International Breast Cancer Conference ever! 

 

Download the programme here

 

quick-links

> Find out more about our on-demand sessions
(starting on 10 March 2021)

> Find out more about our live discussion sessions
(Wednesday, March 17 – Friday, March 19, 2021)

> Find out more about the 2021 St.Gallen International consensus panel sessions
(Saturday, March 20 – Sunday, March 21, 2021)

 

> on-demand sessions

starting on 10 March 2021

Session 1: News in breast cancer care since St. Gallen 2019: challenges and opportunities

15 min. per lecture

Unmet challenges in systemic therapy (Harold Burstein, USA)

Breast surgery – where do we go? (Michael Gnant, Austria)

What patients want: Tradeoffs, preferences and thresholds (Tanja Spanic, Europa Donna)

Accelerating progress to innovation for patients: Trial design and risk stratification (Meredith Regan, USA)

Global challenges in breast cancer detection and treatment (Carlos Barrios, Brazil)

Session 2: Care for patients with HER2-positive breast cancer

15 min. per lecture

Neoadjuvant and adjuvant treatment (Nadia Harbeck, Germany)

HER2 heterogeneity (Aleix Prat, Spain)

Can we prevent brain metastases? (Nancy Lin, USA)

Accelerating progress from advanced to early breast cancer (Hope Rugo, USA)

Session 3: Care for patients with ER+ breast cancer

15 min. per lecture

Adjuvant endocrine therapy  (pre- and postmenopausal) (Eric Winer, USA)

Neoadjuvant endocrine therapy (Steven Johnston, UK)

Why does endocrine therapy work and why does it stop working (Fabrice André, France)

Accelerating progress from advanced to early breast cancer (SERDS, PI3Kinhibitors, other novel agents) (Dave Cescon, Canada)

Session 4: Predictive and prognostic biomarkers in patients with breast cancer

15 min. per lecture

Tumor infiltrating lymphocytes (Carsten Denkert, Germany)

Genomic changes with therapy and detection of molecular recurrence (Nicholas Turner, UK)

Is lobular breast cancer different and should it be treated differently? (William Gradishar, USA)

Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (Martine Piccart, Belgium)

Genetic testing in patients with triple negative or hereditary breast cancer (Judy Garber, USA)

30 min.

Special lecture I

Integrating CDK 4-6 in the treatment of patients with early breast cancer (Sibylle Loibl, Germany)

Session 5: Optimal locoregional therapy: treating the axilla in women with breast cancer

15 min. per lecture

Axillary surgery in node-positive breast cancer (Walter Weber, Switzerland)

Omitting surgical staging of the axilla (Tari King, USA)

Risk adapted regional node irradiation (Philip Poortmans, France)

Adjuvant decision making in the era of limited nodal information (Sharon Giordano, USA)

Session 6: Local treatment of patients with breast cancer

15 min. per lecture

Standards in breast conservation and oncoplastic surgery (Florian Fitzal, Austria)

Breast surgery after neoadjuvant treatment (Jörg Heil, Germany)

Type/timing of reconstruction when post-mastectomy radiotherapy is planned (Andrea Pusic, USA)

State of the art in DCIS: who needs surgery, radiotherapy, endocrine therapy (Boon Chua, Australia)

Session 7: Optimal care of women with triple negative breast cancer

15 min. per lecture

Neoadjuvant and adjuvant treatment (Lisa Carey, USA)

Immuno-oncology treatment in early stage TNBC (Sherene Loi, Australia)

Accelerating progress from advanced to early breast cancer for TNBC (Giuseppe Curigliano, Italy)

Surgery and prophylactic surgery in hereditary breast cancer (Monica Morrow, USA)

PARP inhibitors in treatment of early stage breast cancer (Andrew Tutt, UK)

Session 8: Caring for breast cancer survivors

15 min. per lecture

Lifestyle and sexual health (Inez Vaz Luis, France)

Late toxicity of treatment (including bone health) (Bent Ejlertsen, Denmark)

Fertility preservation (Olivia Pagani, Switzerland)

Surveillance and follow-up (Ann Partridge, USA)

Session 9: Neoadjuvant approach in patients with early breast cancer

15 min. per lecture

Evaluation of the breast cancer patient (patient assessment, staging, planning) (Isabella Rubio, Spain)

Pathology after neoadjuvant treatment – how to assess residual disease (Giuseppe Viale, Italy)

The meaning of residual disease (Ian Krop, USA)

How to work together – the coordination of the multidisciplinary breast team (Emiel Rutgers, The Netherlands)

Session 10: Special treatment challenges in patients with early breast cancer

15 min. per lecture

Management of breast cancer in elderly patients (Matti Aapro, Switzerland)

Management of breast cancer in men (Fatima Cardoso, Portugal)

Locally advanced breast cancer (Stephan Aebi, Switzerland)

Oligometastatic disease – optimal treatment for long-term survival (Javier Cortes, Spain)

Optimizing care in cultures with limited resources: choices and priorities (Andre Ilbawi, WHO Cancer Control Programme)

 

> back to top

 

 

> live discussion sessions

 

During the live discussion sessions, all speakers from the respective on-demand session will be present live to further discuss their lectures. Discussions will be facilitated by distinguished moderators and chairs.

Questions and discussion points can be submitted by registered participants either already while watching the on-demand lectures (strongly preferred!), but also during the live discussion sessions.

Join the live discussion sessions to be part of the scientific dialogue!

 

Wednesday, 17 March 2021

14.00-14.40 (CET)

Session 2: Care for patients with HER2-positive breast cancer

Chair: Harold Burstein (USA)
Co-Chairs: Sibylle Loibl (Germany), Carlos Barrios (Brazil)

14.55-15.35 (CET)

Session 3: Care for patients with ER+ breast cancer

Chair: Michael Gnant (Austria)
Co-Chairs: Philip Poortmans (Belgium), Masakazu Toi (Japan)

15.50-16.30 (CET)

Session 4: Predictive and prognostic biomarkers in patients with breast cancer

Chair: Beat Thürlimann (Switzerland)
Co-Chairs: Giuseppe Viale (Italy), Aleix Prat (Spain)

 

Thursday, 18 March 2021

12.00-12.30 (CET)

ESO Umberto Veronesi Memorial Award Lecture:
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy, Fatima Cardoso (Portugal)
pre-recorded

Introduction by Franco Cavalli (Switzerland)

14.00-14.40 (CET)

Session 5: Optimal locoregional therapy: treating the axilla in women with breast cancer

Chair: Walter Weber (Switzerland)
Co-Chairs: Michael Gnant (Austria), Meredith Regan (USA)

14.55-15.35 (CET)

Session 6: Local treatment of patients with breast cancer

Chair: Monica Morrow (USA)
Co-Chairs: Sherene Loi (Australia), Zhiming Shao (China)

15.50-16.30 (CET)

Session 9: Neoadjuvant approach in patients with early breast cancer

Chair: Sibylle Loibl (Germany)
Co-Chairs: Giuseppe Curigliano (Italy), Nadia Harbeck (Germany)

 

Friday, 19 March 2021

12.00-12.30 (CET)

St.Gallen Oncology Conferences Best Poster Awards 2021
pre-recorded

Introduction by Walter Weber (Switzerland)

14.00-14.40 (CET)

Session 7: Optimal care for women with triple negative breast cancer

Chair: Giuseppe Curigliano (Italy)
Co-Chairs: David Cameron (United Kingdom), Carlos Barrios (Brazil)

14.55-15.35 (CET)

Session 8: Caring for breast cancer survivors

Chair: Meredith Regan
Co-Chairs: Ann Partridge (USA), Eun Sook Lee (Korea)

15.50-16.30 (CET)

Session 10: Special treatment challenges in patients with early breast cancer

Chair: Fatima Cardoso (Portugal)
Co-Chairs: Beat Thürlimann (Switzerland), Carlos Barrios (Brazil)

 

 

> 2021 St.Gallen International consensus panel sessions

 

Saturday, 20 March 2021

13.30-14.00 (CET)

Aron Goldhirsch Memorial Lecture:
Evolution of adjuvant therapies across the time and the future of cooperative academic clinical research groups, David Cameron (United Kingdom)
pre-recorded

Introduction by Alan Coates (Australia)
Co-Chair: Michael Gnant (Austria)

14.00-16.15 (CET)

St.Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 – Part I

Chair: Eric Winer (USA)
Co-Chairs: Harold Burstein (USA), Michael Gnant (Austria), Meredith Regan (USA), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

 

Sunday, 21 March 2021

13.30-14.00 (CET)

2021 St.Gallen International Breast Cancer Award Lecture:
The contribution of radiotherapy to personalised care of patients with early breast cancer, Philip Poortmans (Belgium)
pre-recorded

Introduction by Beat Thürlimann (Switzerland)
Co-Chair: Giuseppe Curigliano (Italy)

14.00-16.15 (CET)

St.Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 – Part II

Chair: Eric Winer (USA)
Co-Chairs: Harold Burstein (USA), Michael Gnant (Austria), Meredith Regan (USA), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

> back to top

 

 

Members of the St.Gallen International breast cancer consensus panel 2021:

to be completed

Stephan Aebi (Switzerland)Jens Huober (Germany)
Fabrice André (France)Andre Ilbawi (WHO Cancer Control Programme)
Carlos Barrios (Brazil)Steven Johnston (UK)
Jonas Bergh (Sweden)Sibylle Loibl (Germany)
Hervé Bonnefoi (France)Monica Morrow (USA)
Denisse Bertel Morales (Peru)Ann Partridge (USA)
Sara Brucker (Germany)Martine Piccart (Belgium)
Harold Burstein (USA)Philip Poortmans (Belgium)
David Cameron (UK)Aleix Prat (Spain)
Fatima Cardoso (Portugal)Meredith Regan (USA
Boon Chua (Australia)Isabella Rubio (Spain)
Eva Ciruelos (Spain)Hope Rugo (USA)
Marco Colleoni (Italy)Emiel Rutgers (The Netherlands)
Giuseppe Curigliano (Italy)Vladimir Semiglazov (Russia)
Suzette Delaloge (France)Zhiming Shao (PR China)
Carsten Denkert (Germany)Felix Sedlmayer (Austria)
Peter Dubsky (Switzerland)Tanja Spanic (Europa Donna)
Bent Ejlertsen (Denmark)Petra Tesarova (Czech Republic)
Eun Sook Lee (South Korea)Beat Thürlimann (Switzerland)
Florian Fitzal (Austria)Sergei Tjulandin (Russia)
Prudence Francis (Australia)Masakazu Toi (Japan)
Viviana Galimberti (Italy)Maureen Trudeau (Canada)
Heba Gamal (Egypt)Nicholas Turner (UK)
Judy Garber (USA)Inez Vaz Luis (France)
Michael Gnant (Austria)Giuseppe Viale (Italy)
William Gradishar (USA)Toru Watanabe (Japan)
Bahadir M. Gulluoglu (Turkey)Walter Weber (Switzerland)
Nadia Harbeck (Germany)Eric P. Winer (USA)
Chiun-Sheng Huang (Taiwan)Binghe Xu (PR China)
Jiang Zefei (PR China)

 

> back to top

subject to changes – sign-up for our newsletter to be always informed about the latest updates

registration

 

We are pleased to offer you a fully-virtual, CME-accredited St.Gallen International Breast Cancer Conference from 17  21 March 2021, including our outstanding scientific programme and of course the renowned St.Gallen Consensus on the optimal treatment of early breast cancer.

Registration fees

Register here and be part of this unique experience – let’s make SG-BCC 2021 unforgettable!

 

Regular fee from
1 February 2021
Early-bird fee until
31 January 2021
Regular participantEUR 395.00EUR 295.00
Students/Residents in training*EUR 125.00EUR 95.00
Nurse*EUR 125.00EUR 95.00
Emerging economies**EUR 125.00EUR 95.00

 

The registration fee includes:
*A letter from the Head of the Department is requested as a proof
**Emerging economies: Applies to individuals from low and lower-middle-income economies according to the World Bank listing

  • online access to the virtual conference
  • possibility to interact with speakers (Q&A), attendees (networking area) or industry representatives (virtual exhibition)
  • admission to the virtual industrial exhibition
  • admission to the virtual poster exhibition
  • certificate of attendance upon submission of an online feedback questionnaire after the conference

 

CME credit points

Participants can obtain a certificate of attendance after the 17th St.Gallen International Breast Cancer Conference. An application for accreditation with CME credit points by the Accreditation Council of Oncology in Europe (ACOE) and the European Union of Medical Specialist (UEMS) will be sent.

 

Official Italian Agency for AIFA Procedure

St. Gallen Oncology Conferences has assigned Alijet & Fargo International to collect applications from Italian delegates and from Italian Pharmaceutical companies for the 17th St. Gallen International Breast Cancer Conference:

Benedetta Cambria
Alijet & Fargo International srl
via P.Maroncelli 46-50
50137 Firenze
Phone: +39 (0)55600555
EMAIL: B.CAMBRIA@ALIFARGOINT.IT

 

Contact

Mondial Congress & Events Mondial GmbH & Co. KG
Daniela Bierbaum
Operngasse 20b
AT-1040 Vienna, Austria
bcc21@mondial-congress.com
Tel.: +43 1 58804-154 Fax: +43 1 58804-185


 

Sign-up for our newsletter at the bottom of this page so that you won’t miss any important updates.

award winners

 

St.Gallen International Breast Cancer Award Winner 2021

The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) proudly announces the recipient of the “St.Gallen International Breast Cancer Award 2021“, which will be delivered during the 17th St.Gallen International Breast Cancer Conference, 17-21 March, 2021 to:

Prof. Philip Poortmans
Iridium Netwerk & University of Antwerp, Belgium

> find out more about Prof. Philip Poortmans


 

ESO Umberto Veronesi Memorial Award Winner 2021

Fatima Cardoso, MD
Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
President, ABC Global Alliance

> find out more about MD Fatima Cardoso

abstracts

 

Abstract submission for the 17th St.Gallen International Breast Cancer Conference 2021 is closed! We really appreciate your profound and interesting contributions that are sure to advance our field in the years to come.

 

Book of Abstracts

We are pleased to publish herewith the list of all accepted abstracts:

> List of abstracts

Further all abstracts will be published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. The respective link can be found on the conference website as of March 17, 2021.

 

ePoster visibility during the conference

Within the virtual conference, all accepted submissions will be displayed in an ePoster gallery, which will be available as of March 10, 2021. You will be able to contact abstract presenters via the meeting hub, which is the networking area within the conference platform.

 

Poster awards

The scientific committee honours the best three poster abstracts with the St.Gallen Oncology Conferences Best Poster Award 2021. All three awards are endowed with a prize money of € 500,-.

The awardees will be presented in a virtual poster ceremony on Friday, March 19, 2021 (12:00 – 12:30 CET).

 

Sign-up for our newsletter at the bottom of this page so that you won’t miss any important deadline.

exhibition & sponsorship opportunities

 

The 17th St.Gallen International Breast Cancer Conference 2021 is going forward to a fully virtual meeting. The digital conference platform offers you unique opportunities to present your company to a most interested professional audience as a “major player” in the field. There are various kinds of options for you to participate and build up and expand your network within the global oncology community, dedicated to improve the outcome of early breast cancer treatment.

Here is what you can expect:

  • A unique platform with a high quality scientific programme, CME accredited, taking place on 17-21 March 2021
  • Exclusive satellite symposium integrated in the on-demand offer available to all participants after the congress
  • A virtual exhibition allowing participants to get informed about your latest treatment and research
  • Customized marketing opportunities through the website and virtual congress platform, newsletters, etc.
  • No travel necessary, no infrastructure or staff costs – take part in the congress from your office

Find all our exciting exhibition and sponsorship opportunities here:

> SG-BCC 2021 industry brochure

> online application for exhibition

 

In order to sign up for sponsorship, you have to complete the online sponsorship application form via the above link. By completing the exhibition application form, companies agree to the Sponsorship – Participation Terms and Conditions. The booking is legally binding upon submission.

 

Below you can find a summarized but not exhaustive sponsorship opportunity list from our brochure:

  • Virtual Exhibition Package
  • Premium Virtual Exhibition Package
  • Digital Advertising on the Virtual Conference Platform
  • Sponsor the Virtual SG-BCC 2021 Tutorial Video
  • Publication of lectures of the scientific sessions of the conference in a Supplement of the Journal THE BREAST (Elsevier)
  • and many more

 

satellite symposia

All satellite symposia slot are already booked out, however we offer alternative options, for more information please contact Ellen Valckenaere (valckenaere@mondial-congress.com)

We thank our partners and sponsors who support the 17th St.Gallen International Breast Cancer Conference.

co-operating partner

sponsoring partner

promotional partner

satellite symposia programme

 

Wednesday, 17 March 2021
10.30 – 12.00 (CET)Answer in CME (Lilly)
12.15 – 13.45 (CET)F. Hoffmann-La Roche
16.45 – 18.15 (CET)Pfizer Oncology
Thursday, 18 March 2021
12.45 – 13.45 (CET)Seattle Genetics
16.45 – 18.45 (CET)Daiichi Sankyo Europe GmbH
18.30 – 19.30 (CET)NOVARTIS
Friday, 19 March 2021
12.45 – 13.45 (CET)Exact Sciences
16.45 – 18.15 (CET)PIERRE FABRE

 

 

Wednesday, 17 March 2021

 


10.30 – 12.00 (CET)

When Recurrence is in the Cards: Recognizing and Addressing Risk in Patients with HR-positive, HER2-negative Early Breast Cancer

Faculty:
William J. Gradishar, USA
Nadia Harbeck, Germany

  • Welcome and Introductions
  • Identifying Which Way the Deck is Stacked for Patients with Early Breast Cancer
  • Showing Your Cards When it Comes to Risk Assessment for Early Breast Cancer
  • Adressing the Cards Dealt with Evolving Treatment for Early Breast Cancer
  • Using the Cards Up Your Sleeve to Optimize Treatment for Early Breast Cancer
  • Q&A
  • Take Home Learnings

> back to top

 


12.15 – 13.45 (CET)

Advancing care for patients with early breast cancer
  • 12:15–12:20 Welcome and introduction
    Dr Giampaolo Bianchini, Italy
  • 12:20–12:40 Making optimal treatment decisions for patients with HER2-positive eBC
    Dr Giampaolo Bianchini, Italy
  • 12:40–12:50 Improving treatment beyond efficacy for patients with HER2-positive eBC
    Prof. Christian Jackisch, Germany
  • 12:50–13:10 The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer
    Prof. Peter Schmid, UK
  • 13:10–13:20 Beyond efficacy: Patient-reported outcomes from cancer immunotherapy trials in early triple negative breast cancer
    Dr Elizabeth Mittendorf, USA
  • 13:20–13:35 Panel discussion
    Moderated by Dr Giampaolo Bianchini, Italy
  • 13:35–13:40 Dr Giampaolo Bianchini

> back to top

 


16.45 – 18.15 (CET)

The value of experience: Improving patient outcomes in a new era of clinical evidence
  • Defining the moment: Treatment discussions in HR+/HER2- breast cancer
    Giuseppe Curigliano, Italy
  • The era of genetic testing: Treatment selection for patients with germline BRCA-mutated locally advanced or metastatic breast cancer
    Paul Cottu, France
  • Q&A
    Giuseppe Curigliano, Italy
    Paul Cottu, France
  • The time is now: Harnessing the value of real-world evidence in clinical decision making
    Winson Cheung, Canada
    Paul Cottu, France
  • Q&A
    Winson Cheung, Canada
    Paul Cottu, France
  • Looking forward: Future directions of treatment in HR+/HER2- metastatic breast cancer
    Giuseppe Curigliano, Italy

> back to top

 

 

Thursday, 18 March 2021

 


12.45 – 13.45 (CET)

Experts exploring HER2CLIMB

Faculty:
Dr Stephanie Sutherland, UK (Chair)
Prof. Sibylle Loibl, Germany
Dr Mafalda Oliveira, Spain

  • Understanding the HER2CLIMB study design
  • Exploring the data: HER2CLIMB efficacy and safety
  • Diving Deeper: HER2CLIMB subgroups
  • Live Q&A session
  • Short closing statement

> back to top

 


16.45 – 18.15 (CET)

Next-generation antibody-drug conjugates: New hope for HER2
  • Opening remarks
    Jean-Yves Pierga, France (Co-Chair)
  • The innovative mode of action of next-generation antibody-drug conjugates (ADCs)
    Matthias Peipp, Germany
  • Next-generation ADCs in the treatment of advanced breast cancer (ABC)
    Rupert Bartsch, Austria
  • New hope for HER2: Early intervention in HER2-positive breast cancer
    Sibylle Loibl, Germany
  • New recommendations for HER2: Guideline update
    Fatima Cardoso, Portugal
  • New paradigm for HER2: Place of the next-generation ADCs in the treatment landscape
    Panel Discussion and Q&A
    All speakers
  • Closing remarks
    Nadia Harbeck, Germany (Co-Chair)

> back to top

 


18.30 – 19.30 (CET)

Reimagining Treatment of HR+, HER2– EBC

Speakers:
Aleix Prat, Spain
Giuseppe Curigliano, Italy

  • Opening remarks
  • Recurrence Risk: A Clinical or Genomic Assessment?
  • Who May Benefit from CDK4/6i in the EBC Setting?
  • What Might the Future Look Like in EBC?
  • Live Q&A session
  • Closing remarks

> back to top

 

 

Friday, 19 March 2021

 


12.45 – 13.45 (CET)

Confidence in treatment decisions for HR+, HER2- early breast cancer patients

Chair:
Mark Harries, UK

  • Recent landmark RxPONDER results: impact on treatment decisions for node-positive patients
    Suzette Delaloge, France
  • An integrated view of the latest clinical evidence
    Giuseppe Curigliano, Italy
  • What will we do on Monday morning?
    Moderated by Mark Harries with the entire panel
  • Patient cases and discussion

> back to top

 


16.45 – 18.15 (CET)


EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES

Patient cases in HER2+ early breast cancer

  • Welcome and introduction
    Prof. S. Loibl (Chair), Germany
  • Practice update | Evolving concepts in HER2+/HR+ early breast cancer
    Prof. S. Loibl
  • Managing risk | A patient with node-positive HER2+/HR+ breast cancer after adjuvant treatment
    Prof. R. Bartsch, Austria
  • Check the narrative | Preventing recurrence in a patient after neoadjuvant therapy
    Dr. J. O’Shaughnessy, USA
  • HER experience | Understanding the patient’s perspective
    Panel discussion
    All faculty joined by Ms Laure Guéroult-Accolas, Patients en réseau
  • Live Q&A and close
    Prof. S. Loibl

> back to top

 

press registrations

 

We are inviting members of the press to join us for the virtual SG-BCC 2021 and offer free press registrations for them to cover the event.

 

Registration as press member

For press registration please fill out the online registration form and select “press” for registration type. In case there are any questions contact Mondial Congress & Events, bcc21@mondial-congress.com

 

Press Office

The Conference Secretariat offers journalists full support throughout the meeting. All registered journalists can arrange interviews with physicians and researchers who present their work during the 17th St.Gallen International Breast Cancer Conference. For support arranging an interview, please contact precht@mondial-congress.com outlining the requested interviewee(s), the scope of the interview and availabilities.

 

Media policies

  • Only registered journalists who provided their press credentials prior to the meeting will gain online access. Press registrations are non-transferable.
  • Registration is limited to a maximum of three representatives per media outlet.
  • Financial analysts, sales, advertising, marketing and public relations personnel may not register as press.
  • It is not permitted to record/screen grab any of the official scientific sessions. The use of the St.Gallen International Breast Cancer Conference logo is only allowed with prior written permission of the SONK. It can be requested from the SONK Secretariat.

 

Copyright of presentation material

  • All materials in written or illustrated form presented in the scientific programme are the intellectual property of the authors and all rights reside with them. Recording without proper authorisation by the holder of rights must be considered a violation of copyrights and will be prevented by the organisers of the conference.

 

Embargo breaks for media reporters

Breaking of the embargo policy by a reporter will lead to one or more of the following measures:

  • Immediate suspension of the reporter’s media conference credentials
  • Immediate barring of the reporter and all other members of his/her media outlet from the meeting platform
  • No access to the next meetings for representatives of the media outlet

the St.Gallen Consensus on the optimal Treatment of early breast cancer

 

The St.Gallen International Breast Cancer Conference 2021 will close as usual with an update of the widely acknowledged St.Gallen Consensus on the optimal Treatment of early breast cancer.

In order to allow even more room for discussions on early breast cancer care, the 2021 Consensus will be split out over the weekend, taking place on Saturday, 20 March 2021, and Sunday, 21 March 2021, for the first time.

Ask your questions to the consensus panel! 

For the first time ever, the consensus panel decided that they want to hear your questions directly. The consensus session will take place on both Saturday and Sunday, allowing more room for discussion. Questions for the panel can be submitted during the online registration process.

Get ready for the most interactive St.Gallen International Breast Cancer Conference ever! 

> Register here and contribute to the scientific dialogue

 

The consensus and its related scientific core issues will then be published following the conference, in summer 2021.

The list of all members of the St.Gallen 2021 international breast cancer consensus panel can be found here.

 

Publications 2019:

Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.

 

The BREAST Supplement manuscripts St.Gallen International Breast Cancer Conference 2019

Read the latest THE BREAST Supplement with manuscripts of the 16th St.Gallen International Breast Cancer Conference 2019 here.

 

 

webcasts

 

Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years:

 

 

FAQ – Frequently asked Questions

 

Where can I find the official statement that SG-BCC 2021 will take place as a virtual congress? 

An official statement has been published on the website: https://www.oncoconferences.ch/news/sg-bcc-2021-we-move-to-a-fully-virtual-format/

 

Quicklinks

>Registration

>Accomodation & Travel

>Scientific Programme

>Virtual Conference

>Industry

 

Registration

 

What is included in my registration fee?

The registration fee includes:

  • Online access to the virtual conference
  • Private login code for one device
  • Possibility to interact with speakers (Q&A), attendees (meeting hub) or industry representatives (virtual exhibition)
  • Exclusive access to SG-BCC webcasts
  • Certificate of attendance upon completion of post-session evaluations and a post-congress survey

 

Will I receive a certificate of attendance?

Yes, you will be able to download your certificate of attendance upon completion of post-session evaluations and a post-congress survey.

 

When and how can I register for Virtual SG-BCC 2021 if I have not registered before?

The online registration for Virtual SG-BCC 2021 is already open, more information can be found on the following page: www.sg-bcc.org/#registration

 

Will the registration fee for Virtual SG-BCC 2021 remain the same?

No, St.Gallen Oncology Conferences decided to lower the registration fees for the online meeting while offering the same high value scientific content with top-quality educational sessions and the St.Gallen Consensus meeting on Saturday, 20 March 2021 and Sunday, 21 March 2021

More information is available on the website: www.sg-bcc.org/#registration

If you have already paid the registration fees for the 17th St.Gallen International Breast Cancer Conference in Vienna, your overpayment will be refunded of course. Please contact bcc21@mondial-congress.com if you have any questions.

 

When is the last day to register?

Registration will remain open until the last day of the congress.

>back to top

Accommodation & Travel

 

Is it possible to cancel my accommodation for free?

If you have booked your accommodation through the official SG-BCC 2021 online registration or via Mondial Congress & Events your booking will be cancelled automatically.

St.Gallen Oncology Conferences does not cover any cancellation fees for bookings which have been made through any other platform.

 

Will St.Gallen Oncology Conferences cover costs which may occur for the cancellation of my travel arrangements?

We would kindly ask you to get in contact with the company where you have purchased your ticket (airline, train company, etc.) directly to cancel your booking.
St.Gallen Oncology Conferences / Mondial will not cover any costs for travel arrangements or cancellation costs.

>back to top

Scientific Programme

 

Will the programme for Virtual SG-BCC remain the same as it was planned for the physical conference?

The content of our virtual meeting will offer the same high value as our live meeting, with top-quality educational sessions and live discussions. Some items of the agenda might be slightly changed. Please refer to our website to stay up-to-date concerning programme developments: www.sg-bcc.org/#programme.

 

Will Virtual SG-BCC 2021 be CME accredited?

Yes, an application will be made to the EACCME® for CME accreditation of the conference. Further information will follow as soon as the application process has been completed.

 

I have submitted an abstract for SG-BCC 2021 in Vienna, what happens now?

If accepted, your abstract will be included in the congress supplement and as an e-poster on the congress platform.

Individual notifications informing you about the acceptance of your abstract and further steps will be sent on 25 January 2021.

 

Do I need to be registered to present my abstract and for publication of the abstract?

Yes, you have to be registered for the virtual conference.

>back to top

 

Virtual Conference

 

When and how can I access the virtual conference platform?

If you are registered for Virtual SG-BCC 2021 you will receive a link with your individualized access/ log-in code on the email address you used to register for the congress. You will receive the access / log-in information for the virtual congress platform within 24 hours before the congress starts. If you register during the meeting, you will receive the access/ log-in code immediately (online payment via credit card is required).

 

Can I share the link with others?

No, your personal access can be used by one person only. Your attendance will be tracked during the whole congress to be able to send your CME certificate accordingly.

 

When will the sessions be available via webcast?

The official webcast will become available around one week after the end of the congress. However, before then you will be able to re-watch all sessions you may have missed on the virtual congress platform directly.

 

Is it possible to ask questions to presenters?

Yes, you are able to ask questions during live sessions via the chat function. Presenters will see those questions during the presentation and can answer afterwards. This function will allow a dynamic and interesting communication for all parties involved.

>back to top

Is it possible to ask questions to the consensus panel?

Yes, for the first time ever, the consensus panel decided that they want to hear your questions directly. The consensus session will take place on both Saturday and Sunday, allowing more room for discussion. Questions for the panel can be submitted during the online registration process.

Industry

 

Will there be an online exhibition at Virtual SG-BCC 2021?

Yes, there will be a virtual industry exhibition allowing participants to get informed about the latest products and technologies of our industry partners.

 

I am interested in contributing to Virtual SG-BCC 2021 as a sponsor/exhibitor. How can I get more information?

Please get in touch with Ellen Valckenaere of the SG-BCC 2021 Organising Team, she will provide you with all information you need: valckenaere@mondial-congress.com

>back to top

contact

 

Scientific programme and faculty

St. Gallen Oncology Conferences (SONK)
c/o Tumor and Breast Center ZeTuP
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 00 32
info@oncoconferences.ch

 

Industrial exhibition, satellite symposia, registration, hotel accommodation, networking programme, abstract submission

Mondial Congress & Events
Mondial GmbH & Co. KG
Operngasse 20b, 1040 Vienna / Austria
+43 1 588 04 0
bcc21@mondial-congress.com

COVID-19 Update – join us online worldwide!

 

With the 17th St.Gallen Breast Cancer Conference approaching in just three months, we had to come to some important decisions: While we had hoped that the situation of the pandemic would have allowed us to proceed with the planned “hybrid” setup of our Conference, we feel forced to move to a fully virtual format with SG-BCC 2021. Despite the fact that for Vienna, as for many European cities and countries, the projected public health situation for March 2021 is optimistic (with widespread vaccinations and current lockdowns leading to a rather safe situation), we cannot be sure that reasonable travel options are available not even within Europe, and almost certainly not for many regions in the world. Also, it might be not before late summer until the pandemic is fully under control, and clearly the safety and health of faculty, participants, and staff is our first priority.

Despite the challenges that come with virtualizing SG-BCC 2021, we will certainly organise the best meeting virtually. It is the aim of offering the full programme, including some new features such as livestream discussions, taking into account global time zones. Also, the core Consensus Panel Voting will take place, albeit in a modified format.

The whole Conference will also be available digitally on-demand for for those colleagues who cannot attend live. Furthermore, the St.Gallen Consensus Recommendations will be published as before in a high-ranking journal.

We will keep you informed about important steps. Register now and be part of this unique experience – let’s make SG-BCC 2021 unforgettable!

Register here

Newsletter abonnieren